{
    "Disease activity (follow up: 1 year; assessed with: ACR 70)": {
      "No of studies": ["14"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "ABA+MTX": "109/256 (42.6%)",
        "MTX monotherapy": "69/253 (27.3%)"
      },
      "Effect": {
        "Relative (95% CI)": "RR 1.56 (1.22 to 2.00)",
        "Absolute (95% CI)": "153 more per 1,000 (from 60 more to 273 more)"
      },
      "Certainty": "MODERATE",
      "Importance": "CRITICAL"
    },
    "Disease activity (follow up: 1 year; assessed with: DAS28 CRP (Lower values – > benefit) (MCID -1.02)": {
      "No of studies": ["14"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "ABA+MTX": "256",
        "MTX monotherapy": "253"
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.73 lower (0.98 lower to 0.48 lower)"
      },
      "Certainty": "MODERATE",
      "Importance": "CRITICAL"
    },
    "Remission (follow up: 1 year; assessed with: DAS28-ESR remission <2.6)": {
      "No of studies": ["14", "15"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "ABA+MTX": "176/371 (47.4%)",
        "MTX monotherapy": "109/368 (29.6%)"
      },
      "Effect": {
        "Relative (95% CI)": "RR 1.60 (1.33 to 1.93)",
        "Absolute (95% CI)": "178 more per 1,000 (from 98 more to 275 more)"
      },
      "Certainty": "MODERATE",
      "Importance": "CRITICAL"
    },
    "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)": {
      "No of studies": ["14"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "ABA+MTX": ["0","b"],
        "MTX monotherapy": "0"
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.43 lower (0.91 lower to 0.05 higher)"
      },
      "Certainty": "MODERATE",
      "Importance": "IMPORTANT"
    },
    "Disability (follow up: 1 year; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)": {
      "No of studies": ["14"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["serious", "c"],
      "Other considerations": "none",
      "No of patients": {
        "ABA+MTX": ["256","d"],
        "MTX monotherapy": "253"
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.2 lower (0.31 lower to 0.09 lower)"
      },
      "Certainty": "LOW",
      "Importance": "IMPORTANT"
    },
    "Quality of Life (follow up: 1 year; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)": {
        "No of studies": ["14"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "c"],
        "Other considerations": "none",
        "No of patients": {
        "ABA+MTX": "256",
        "MTX monotherapy": "253"
        },
        "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 2.5 higher (0.77 higher to 4.23 higher)"
        },
        "Certainty": "LOW",
        "Importance": "IMPORTANT"
    },
    "Quality of Life (follow up: 1 year; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)": {
        "No of studies": ["14"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "e"],
        "Other considerations": "none",
        "No of patients": {
        "ABA+MTX": "256",
        "MTX monotherapy": "253"
        },
        "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 1.81 lower (3.58 lower to 0.04 lower)"
        },
        "Certainty": "LOW",
        "Importance": "IMPORTANT"
    },
    "Withdrawal due to lack of efficacy (follow up: 1 year)": {
        "No of studies": ["15"],
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "e"],
        "Other considerations": "none",
        "No of patients": {
        "ABA+MTX": "5/115 (4.3%)",
        "MTX monotherapy": "11/115 (9.6%)"
        },
        "Effect": {
        "Relative (95% CI)": "RR 0.45 (0.16 to 1.27)",
        "Absolute (95% CI)": "53 fewer per 1,000 (from 80 fewer to 26 more)"
        },
        "Certainty": "MODERATE",
        "Importance": "IMPORTANT"
    },
    "Withdrawal due to adverse events (follow up: 1 year)": {
        "No of studies": ["14", "15"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "f"],
        "Other considerations": "none",
        "No of patients": {
        "ABA+MTX": "13/375 (3.5%)",
        "MTX monotherapy": "16/369 (4.3%)"
        },
        "Effect": {
        "Relative (95% CI)": "RR 0.80 (0.39 to 1.64)",
        "Absolute (95% CI)": "9 fewer per 1,000 (from 26 fewer to 28 more)"
        },
        "Certainty": "LOW",
        "Importance": "IMPORTANT"
    },
    "Serious adverse events (follow up: 1 year)": {
        "No of studies": ["14"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "g"],
        "Other considerations": "none",
        "No of patients": {
        "ABA+MTX": "20/256 (7.8%)",
        "MTX monotherapy": "20/253 (7.9%)"
        },
        "Effect": {
        "Relative (95% CI)": "RR 0.99 (0.55 to 1.79)",
        "Absolute (95% CI)": "1 fewer per 1,000 (from 36 fewer to 62 more)"
        },
        "Certainty": "LOW",
        "Importance": "IMPORTANT"
    },
    "Malignancy (follow up: 1 year)": {
        "No of studies": ["14", "15"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "e"],
        "Other considerations": "none",
        "No of patients": {
        "ABA+MTX": "1/371 (0.3%)",
        "MTX monotherapy": "2/368 (0.5%)"
        },
        "Effect": {
        "Relative (95% CI)": "RR 0.60 (0.08 to 4.48)",
        "Absolute (95% CI)": "2 fewer per 1,000 (from 5 fewer to 19 more)"
        },
        "Certainty": "LOW",
        "Importance": "IMPORTANT"
    },
    "Death (follow up: 1 year)": {
        "No of studies": ["14", "15"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["serious", "f"],
        "Other considerations": "none",
        "No of patients": {
        "ABA+MTX": "2/371 (0.5%)",
        "MTX monotherapy": "4/368 (1.1%)"
        },
        "Effect": {
        "Relative (95% CI)": "RR 0.49 (0.09 to 2.67)",
        "Absolute (95% CI)": "6 fewer per 1,000 (from 10 fewer to 18 more)"
        },
        "Certainty": "LOW",
        "Importance": "IMPORTANT"
    },
    "Malignancy (from SRs on harms)": {
        "No of studies": ["13"],
        "content":"The Systematic Review RefID=4638, 2012 (RCTs=3, n=2435) comparing Abatacept + csDMARD vs Placebo + csDMARD among RA showed that for Cancer, the result was RR=0.65 (0.25-1.7) at 1 year.  " 
          }
      
  }
  